Oryzon Genomics, S.A.

Oryzon Genomics, S.A. is a clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics. Founded in 2000 in Barcelona, Spain, the company's core mission is to leverage epigenetics to discover and develop innovative personalized medicines for patients suffering from cancer and central nervous system (CNS) disorders. Its operational headquarters are located in Cornellà de Llobregat, Barcelona, Spain.

Oryzon's therapeutic strategy focuses on targeting lysine specific demethylase 1 (LSD1), a histone modifying enzyme implicated in various human diseases. The company's pipeline includes two primary compounds in clinical development: iadademstat, a selective LSD1 inhibitor for oncology and hematology indications such as acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS-optimized LSD1 inhibitor for CNS and psychiatric disorders, including borderline personality disorder, schizophrenia, and autism spectrum disorder. Additionally, Oryzon has ORY-4001, a selective HDAC6 inhibitor, in preclinical development.

In recent news, Oryzon Genomics received a U.S. patent allowance for its vafidemstat BPD treatment in March 2026 and announced a new U.S. patent covering iadademstat combinations with venetoclax. The company also received EMA clearance for an essential thrombocythemia trial in February 2026. Leadership was strengthened with the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS Programs in February 2026. Oryzon continues to advance its clinical programs, including addressing FDA feedback on the Phase III protocol for vafidemstat in borderline personality disorder, with plans to revise and resubmit. Carlos Buesa serves as the Chief Executive Officer.